Metoclopramide

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Half-lifeThis section has been translated automatically.

2,3–8,3 h

Pharmacodynamics (Effect)This section has been translated automatically.

Excitation of muscarinic choline receptors by release of acetylcholine; dopamine antagonist.

IndicationThis section has been translated automatically.

Nausea, vomiting, prophylaxis of cytostatic-induced nausea.

Limited indicationThis section has been translated automatically.

Pregnancy (1st trimenon), lactation, depression, children < 14 years, breast cancer in the history, renal insufficiency.

Dosage and method of useThis section has been translated automatically.

2 mg/kg bw i.v. as a short infusion 30 minutes before administration of the cytostatic drug and 1.5/3.5/5.5 and 8.5 hours after administration of the cytostatic drug. Alternatively, 0.5-1 mg/kg bw/hour i.v. starting 2 hours before administration of cytostatics over 24 hours as continuous infusion.

Undesirable effectsThis section has been translated automatically.

Malignant neuroleptic syndrome (extrapyramidal symptoms, subfebrile temperatures, polypnoea, tachycardia, salivation, sweating, loss of consciousness), CNS disorders, galactorrhea, gynecomastia, hyperprolactinemia, menstrual disorders.

InteractionsThis section has been translated automatically.

See Table 1.

ContraindicationThis section has been translated automatically.

Prolactinoma, intestinal obstruction, epilepsy, extrapyramidal symptoms, children < 2 years, gastrointestinal bleeding, MAO-inhibitor intake, pheochromocytoma.

PreparationsThis section has been translated automatically.

Gastrosil; Paspertine; MCP

TablesThis section has been translated automatically.

Essential interactions of metoclopramide

Alimemazine

extrapyramidal symptoms ↑

Anticholinergics

mutual effect ↓

Antidepressants, tricyclic

extrapyramidal symptoms ↑, fatigue ↑

Atovaquon

Atovaquone effect ↓

Barbiturates

Tiredness ↑

Ciclosporin A

Ciclosporin levels ↑

Cimetidine

Cimetidine level ↓, intake 2 hours apart

Digoxin

Digoxin level ↓

Ipatropium bromide

mutual effect ↓

Lisurid

Lisuride effect ↓

Neuroleptics

extrapyramidal symptoms ↑

Sleeping pills

Tiredness ↑

Scopolamine

mutual effect ↓

Sympathomimetics

Avoid combination

Tranquillizer

extrapyramidal symptoms ↑, fatigue ↑

Authors

Last updated on: 29.10.2020